Loading...
•
Jun 30, 2023
Precigen Q2 2023 Earnings Report
Precigen's financial performance and portfolio prioritization were updated.
Key Takeaways
Precigen reported its Q2 2023 financial results, highlighting a loss from continuing operations of $20.3 million, or $(0.08) per basic and diluted share. The company is prioritizing its portfolio activities to maximize the potential success of PRGN-2012 and has extended its projected cash runway into 2025 through cost-saving measures and a capital raise.
FDA confirmed the ongoing Phase 1/2 study of PRGN-2012 will serve as the pivotal study to support accelerated approval.
Portfolio activities are being prioritized to maximize the potential success of PRGN-2012.
The company's balance sheet is well-positioned for the future due to a capital raise and cost-saving measures.
Projected cash runway has been extended into 2025, exclusive of non-dilutive strategies.
Precigen
Precigen
Forward Guidance
Precigen anticipates continued advancement of its pipeline programs with a focus on key clinical milestones and strategic partnerships to extend its cash runway.
Positive Outlook
- Potential accelerated approval pathway for PRGN-2012
- Prioritization of portfolio activities to maximize PRGN-2012 success
- Advancement of key programs based on AdenoVerse and UltraCAR-T platforms
- Strong balance sheet due to capital raise and cost-saving measures
- Potential for strategic partnerships to further extend cash runway
Challenges Ahead
- Dependence on successful clinical trial outcomes
- Risks associated with regulatory approvals
- Potential challenges in commercializing new therapies
- Uncertainties related to strategic partnerships
- Impact of market competition on product adoption